Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase Clinical Trial

Official title:
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
Myeloid Leukemia, Chronic, Chronic-Phase

Clinical Trial Details

NCT number	NCT00324077
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Withdrawn
Phase	Phase 1
Start date	August 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02348957` - Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
Terminated	`NCT00114959` - Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)	Phase 2
Completed	`NCT00123474` - Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML	Phase 3
Completed	`NCT00510926` - Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase	Phase 2